Project Grant K08AI182489

Award Date 6/3/24
Completion Date 5/31/29
Dollars Obligated $548K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $417,984 to the Scripps Research Institute to support a research project focused on the study of FOXP3 and regulatory T cell fate. The key objectives of the project are to: Identify the biomolecular target and mechanism of action for the small molecule A205804 in inducing functional CD4+ regulatory T cell differentiation...
This five-year $196,992 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports a research career development plan for Dr. Gloria Yiu, M.D., Ph.D., an Assistant Professor of Medicine in Rheumatology at the University of California, Los Angeles (UCLA). The key objectives of this research project are to: 1) enhance endogenous FOXP3 expression in induced pluripotent stem cells...
The federal Project Grant award of $597,542 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research at Emory University to investigate the metabolic and epigenetic regulation of regulatory T cells (Tregs) in the skin. The research aims to dissect the specific metabolic program governing the homeostasis of skin Tregs and elucidate how this metabolic adaptation impacts the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $162,512 to the Regents of the University of Minnesota to investigate the factors that support the expansion and function of long-lived effector CD8 T cells within the memory compartment. The key objectives are to determine what pro-inflammatory cytokines and other factors promote the formation and...
This R03 project grant, awarded by the National Center for Advancing Translational Sciences (NCATS) under CFDA Program 93.350, aims to comprehensively identify metabolic enzymes that control the generation of TCF1+ progenitor CD8+ T cells, which are critical for durable anti-tumor immune responses. The $169,500 award, spanning from September 1, 2024 to August 31, 2026, will fund two key research objectives: Identifying metabolic enzymes whose loss alters T cell differentiation and the TCF1+...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $194,740 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The purpose of this 5-year grant is to characterize the development of lung-resident self-antigen-specific regulatory T cells (Tregs) following acute lung injury in an experimental mouse model. The research aims to understand how these...
This $163,080 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a multidimensional analysis of the regulatory T cell (Treg) response in children with severe viral pneumonia. The primary investigator will conduct research to determine if Treg cells have impaired reparative functions during severe viral pneumonia in juvenile mice, investigate how the age-specific lung microenvironment affects...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $195,894.00 to The Washington University to study the mechanisms contributing to T cell dysregulation in STAT3 gain-of-function (GOF) syndrome. The primary scientific goal is to investigate critical interactions between T and B cells, as well as the development, polarization, and function of these cells, in order to...
This Project Grant award of $775,992.00 from the National Heart, Lung, and Blood Institute (NHLBI)'s Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of regulatory T cells (Tregs) and glucocorticoid signaling in the resolution of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The key objectives are to determine the function of Treg glucocorticoid receptor (GR) signaling and the impact of exogenous glucocorticoid...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to investigate the role of the PPARD/CIITA/MHCII axis in regulating regulatory T cell (Treg) function and its impact on tumor immunity. The $276,450 award to the Salk Institute for Biological Studies will fund experiments to define the molecular mechanisms by which MHCII expression in Tregs is regulated by...

MECHANISMS OF REGULATORY T CELL ADAPTATION TO INFLAMMATION - PROJECT SUMMARY/ ABSTRACT THIS IS AN APPLICATION FOR A K08 AWARD FOR DR. NIKOLAOS SKARTSIS, AN ASSISTANT PROFESSOR OF MEDICINE AT MAYO CLINIC COLLEGE OF MEDICINE AND SCIENCE, ROCHESTER, MN. DR. SKARTSIS IS ESTABLISHING HIMSELF AS A YOUNG INVESTIGATOR IN CLINICAL SCIENCE RESEARCH WITH A TRANSLATIONAL FOCUS ON THE IMPACT OF INFLAMMATION ON REGULATORY T CELLS (TREGS) WITH AN OVERARCHING GOAL TO DESIGN THE NEXT GENERATION TREG-ENHANCING THERAPIES FOR TRANSPLANTATION. THIS K08 AWARD WILL PROVIDE DR. SKARTSIS WITH THE SUPPORT NECESSARY TO ACCOMPLISH THE FOLLOWING GOALS: (1) TO BECOME AN EXPERT TRANSLATIONAL RESEARCHER IN TREG BIOLOGY AS IT RELATES TO INFLAMMATION; (2) TO DEVELOP ALL THE TOOLS NECESSARY TO HAVE AN INDEPENDENT TRANSLATIONAL RESEARCH CAREER. TO ACHIEVE THESE GOALS, DR. SKARTSIS HAS ASSEMBLED A MULTIDISCIPLINARY MENTORING TEAM OF EXPERTS COMPRISED OF HIS PRIMARY MENTOR, DR. WILLIAM FAUBION, EXPERT IN BASIC AND TRANSLATIONAL RESEARCH IN TREG BIOLOGY AND EPIGENETICS; CO-MENTORS ARE: DR. CORNELIA WEYAND, EXPERT IN IMMUNOMETABOLISM; DR. VIRGINIA SHAPIRO, EXPERT IN T CELL ACTIVATION AND MATURATION; DR. MARK STEGALL, EXPERT IN CLINICAL TRIALS IN KIDNEY TRANSPLANTATION, AND DR. VESNA GAROVIC, EXPERT IN IMMUNOLOGICAL MECHANISMS OF PREECLAMPSIA. HE HAS ESTABLISHED COLLABORATIONS WITH DR. SUN, EXPERT IN BIOINFORMATICS, AND DR. WANGENSTEEN, EXPERT IN CRISPR SCREENS. THE IMPACT OF INFLAMMATORY SIGNALS ON TREGS IS NOT WELL UNDERSTOOD DESPITE THE PIVOTAL CONTRIBUTION OF TREGS TO TERMINATE IMMUNE RESPONSES AND MAINTAIN IMMUNE SYSTEM HOMEOSTASIS. THE CENTRAL HYPOTHESIS FOR THIS PROPOSAL IS THAT HUMAN TREGS CAN POSITIVELY RESPONSE TO PROINFLAMMATORY CYTOKINES BY STABILIZING THEIR CELL LINEAGE, WHILE CLONALLY EXPAND TO SCALE TO INFLAMMATION. MOLECULAR MECHANISMS THAT CONTROL HUMAN TREG LINEAGE STABILITY AND PROLIFERATION IN INFLAMMATION ARE NOT FULLY UNDERSTOOD, WHICH WILL BE THE FOCUS OF HIS RESEARCH IN THE NEXT 5 YEARS. IN AIM 1, DR. SKARTSIS WILL STUDY THE TRANSCRIPTIONAL AND EPIGENETIC CHANGES INDUCED BY TNFR2 THAT PROMOTE FOXP3 EXPRESSION IN TREGS. IN AIM 2, HE WILL ANALYZE THE TRANSCRIPTIONAL AND METABOLOMIC CONTROL OF TREG PROLIFERATIVE FITNESS UNDER INFLAMMATORY CONDITIONS. THIS PROPOSAL REPRESENTS AN INNOVATIVE APPROACH TO STUDYING TREG BIOLOGY BECAUSE IT INCORPORATES CRISPR GENE EDITING, FUNCTIONAL GENOMICS, AND IN-VIVO DISEASE MODELING IN HUMANIZED NSG MICE TO DISSECT THE IMPACT OF INFLAMMATORY SIGNALS ON TREG HOMEOSTASIS THAT HAVE NOT PREVIOUSLY APPLIED TOGETHER IN TREG STUDIES IN TRANSPLANTATION OR AUTOIMMUNE DISEASES. THIS PROJECT ADDRESSES A MAJOR GAP IN OUR KNOWLEDGE OF THE IMPACT OF INFLAMMATION ON TREGS, AND THE TRAINING PLAN IT REQUIRES WILL FORM THE BASIS FOR A COMPELLING R01 GRANT APPLICATION TO HARNESS THE MOLECULAR PATHWAYS THAT PROMOTE TREG SURVIVAL AND FUNCTION UNDER INFLAMMATORY CONDITIONS TO DESIGN THE NEXT GENERATION OF TREG ENHANCING THERAPIES IN TRANSPLANTATION AND AUTOIMMUNE DISEASES.

Posted 6/3/24, 12:00 AM